ABBV Stock Price Today (July 2026) — AbbVie Inc. Analysis & Key Metrics 2026-07-17
AbbVie Inc. (ABBV) is trading at $254.49, up 0.04% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $254.38 (-0.0% upside).
- Volatility remains elevated (24.10% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (12.40% YoY) alongside significant competitive pressures.
ABBV Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
AbbVie Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $508.16B
P/E Ratio
Forward P/E: 15.47
Revenue Growth
Year over Year
Analyst Target
+-0.0% upside potential
Key Investor Questions About ABBV
What investors need to know before buying
Based on current market data, ABBV presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 65.12)
- Fundamentals say: Mixed signals (nuanced financial profile)
ABBV's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ABBV investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $72.91B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, ABBV stock traded between $184.39 and $255.99—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 24.10% annualized volatility and β=0.35, the stock exhibits low sensitivity to market moves—making ABBV suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
The Real Question Buried Inside Merck Stock's Premium Price
The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.
AbbVie (ABBV) Wins EU Approval For Boey Frown Line Treatment In Europe
Allergan Aesthetics, an AbbVie company (NYSE:ABBV), received European Commission approval for Boey (trenibotulinumtoxinE). Boey is described as the first rapid onset, short duration neurotoxin for the treatment of frown lines available in Europe. This approval gives AbbVie a differentiated addition to its aesthetics portfolio in Europe, an area where the company already has an established presence. By targeting frown lines with a rapid onset profile and shorter treatment duration, Boey is...
VYM’s $94.6 Billion Portfolio Beats Treasury Yields with Dividend Kings Leading the Way
With 10-year Treasuries near 4.62%, VYM's $94.6 billion portfolio faces a real test from risk-free yields, and two familiar names inside the fund are quietly raising red flags about future income growth.
Why Healthcare Stocks Look Like a Haven in This Market
Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.
Why Abbott Stock Is Having Its Best Day in 24 Years
Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?
ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31.
The Real Engine Behind Johnson & Johnson Stock's Next Climb
While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.
What Could Push LLY Stock Higher From Here?
While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.
Johnson & Johnson CFO Says This Drug Is Outperforming ‘Almost Any Launch’ in Recent Memory
Johnson & Johnson’s second-quarter earnings were met with a shrug on Wall Street, but one of the drugmaker’s top executives insists the most powerful growth drivers are just starting to pick up speed. J&J on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated. “I think the second quarter was just an affirmation of the first quarter,” Chief Financial Officer Joe Wolk said in an interview with Barron’s. “Our pharmaceutical unit continues to thrive, surpassing $16 billion in sales for the first time ever in the company’s history.”
Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?
ABBV stock rallies 9% YTD as Skyrizi and Rinvoq offset Humira declines, but can its pipeline, neuroscience growth and Apogee deal sustain long-term momentum?
Frequently Asked Questions
Common investor questions about AbbVie Inc.
AbbVie Inc. (ABBV) is currently trading at $254.49. The RSI (14-day) is at 65.1, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $254.38 implies 0.0% downside from current levels. Volatility is moderate at 24.1% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for AbbVie Inc. (ABBV): The trailing P/E ratio is 124.75, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 15.47, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.41, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is -66.80. Price-to-Sales is 7.16. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering ABBV, the consensus price target is $254.38. This represents a 0.0% downside from the current price of $254.49. The range spans from a low target of $200.00 to a high target of $328.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, AbbVie Inc. (ABBV) pays a dividend with a current yield of approximately 2.72%. The annualized dividend rate is $6.74 per share. The payout ratio is 326.0%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was 2026-07-15T00:00:00.000Z.
Key risks for AbbVie Inc. (ABBV) investors include: 1. Unsustainable dividend payout ratio (326%) could lead to a dividend cut. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is AbbVie Inc.'s (ABBV) current debt and financial health profile: Total debt stands at $72.91B. The current ratio is 0.80, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.52. The company holds $9.39B in cash and equivalents. Free cash flow is positive at $20.81B, providing a cushion for debt servicing and shareholder returns.